Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
InvestorService: Genmab, to Present at ABN AMRO 2004 Biotech, Specialty Pharma and Generics Conference6 May 2004
Genmab, Capital Increase in Genmab as a Result of Employees' Warrant Exercise6 May 2004
Genmab, articles of association May 6, 20046 May 2004
InvestorService: Genmab, Participates in Merrill Lynch's Mid Cap Healthcare Conference4 May 2004
Genmab, quarterly report Q1 20044 May 2004
Genmab, Announces 2004 First Quarter Results4 May 2004
Genmab, announces Positive HuMax-CD4 Phase II Lymphoma Data28 Apr 2004
Genmab, Licenses Cancer Target from Ganymed
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
26 Apr 2004
Genmab, Capital Increase in Genmab as a Result of Employees' Warrant Exercise20 Apr 2004
Genmab, articles of association dated April 20, 200420 Apr 2004
Genmab, Passing of Genmab A/S' Annual General Meeting – Subsequent Grant of Warrants1 Apr 2004
Genmab, articles of association dated April 1, 20041 Apr 2004
  • Previous
  • 1
  • More pages
  • 142
  • 143
  • 144
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863